趋化因子受体4在人脑胶质瘤中的表达及临床意义

Prognostic and clinicopathological features of glioma with CXCR4 expression

目的探索趋化因子受体4(CXCR4)在人脑胶质瘤中的表达,与临床特征间的关系及其在预后判断中的作用。方法对中国脑胶质瘤基因组图谱计划(CGGA)中305例mRNA芯片数据中进行CXCR4表达分析;在REMBRANDT mRNA芯片数据库、GSE16011 mRNA芯片数据库及TCGA RNA测序数据库中验证CXCR4在胶质瘤中的表达特征。Kaplan-Meier生存曲线及Cox分析评价CXCR4在胶质瘤患者预后判断中的作用,Gene ontology(GO)分析CXCR4正相关表达基因功能。结果 CXCR4表达量随胶质瘤级别增高而升高,CXCR4高表达患者的预后生存期短。CXCR4生物学功能可能与机体免疫、炎症、创伤应答,细胞激活及黏附有关。结论 CXCR4可作为胶质瘤患者预后判断的指标及潜在的治疗靶点。

Objective To investigate the expression pattern and prognostic value of chemokine receptor 4 （ CXCR4 ） in gloma, relationship with clinicopathological features. Methods Whole genome mRNA expression microarray data of 305 WHO II-IV glioma samples from Chinese Glioma Genome Atlas （CGGA） database was obtained as the discovery set. Kaplan-Meier survival analysis was used to estimate the survival distributions. Moreover, Gene ontology was performed for functional annotation of CXCR4. REMBRANDT,GSE16011 mRNA datasets and TCGA RNA sequence dataset were obtained as validation sets. Results CXCR4 over-expression was significantly associated with high grade glioma. Furthermore ,high CXCR4 expression conferred a worse survival. Additionally, GO analysis showed that CXCR4 was associated with immune and inflammatory response, cell activation and adhesion. Conclusion CXCR4 might serve as a novel prognostic biomarker with potential therapeutic implications in glioma.